Ocuphire Pharma Inc (NASDAQ: OCUP)’s stock price has gone rise by 9.40 in comparison to its previous close of 1.33, however, the company has experienced a 15.48% increase in its stock price over the last five trading days. globenewswire.com reported 2024-09-05 that Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery expected in first quarter of 2025 FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia has dosed its first participants.
Is It Worth Investing in Ocuphire Pharma Inc (NASDAQ: OCUP) Right Now?
The 36-month beta value for OCUP is also noteworthy at 0.19. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for OCUP is 23.69M, and at present, short sellers hold a 4.34% of that float. The average trading volume of OCUP on September 20, 2024 was 150.83K shares.
OCUP’s Market Performance
OCUP stock saw an increase of 15.48% in the past week, with a monthly gain of 10.23% and a quarterly increase of -9.06%. The volatility ratio for the week is 5.48%, and the volatility levels for the last 30 days are 6.93% for Ocuphire Pharma Inc (OCUP). The simple moving average for the past 20 days is 14.97% for OCUP’s stock, with a -28.50% simple moving average for the past 200 days.
OCUP Trading at -7.21% from the 50-Day Moving Average
After a stumble in the market that brought OCUP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.67% of loss for the given period.
Volatility was left at 6.93%, however, over the last 30 days, the volatility rate increased by 5.48%, as shares surge +8.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.52% lower at present.
During the last 5 trading sessions, OCUP rose by +15.87%, which changed the moving average for the period of 200-days by -51.17% in comparison to the 20-day moving average, which settled at $1.2710. In addition, Ocuphire Pharma Inc saw -51.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCUP starting from Jayagopal Ashwath, who purchase 3,500 shares at the price of $1.76 back on May 22 ’24. After this action, Jayagopal Ashwath now owns 78,500 shares of Ocuphire Pharma Inc, valued at $6,178 using the latest closing price.
Magrath George, the Chief Executive Officer of Ocuphire Pharma Inc, purchase 5,000 shares at $1.75 during a trade that took place back on May 17 ’24, which means that Magrath George is holding 430,000 shares at $8,772 based on the most recent closing price.
Stock Fundamentals for OCUP
Current profitability levels for the company are sitting at:
- -0.92 for the present operating margin
- 0.71 for the gross margin
The net margin for Ocuphire Pharma Inc stands at -0.86. The total capital return value is set at -0.37. Equity return is now at value -36.01, with -31.95 for asset returns.
Currently, EBITDA for the company is -10.56 million with net debt to EBITDA at 2.75. When we switch over and look at the enterprise to sales, we see a ratio of -0.2. The receivables turnover for the company is 7.13for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.68.
Conclusion
In summary, Ocuphire Pharma Inc (OCUP) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
